400 related articles for article (PubMed ID: 22908915)
1. Eplerenone for the treatment of cardiovascular disorders.
Watanabe M; Krum H
Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological sheet: eplerenone (Inspra), orally].
J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
[No Abstract] [Full Text] [Related]
5. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
6. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
George J; Struthers AD
Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
Epstein M
Nephrol Dial Transplant; 2003 Oct; 18(10):1984-92. PubMed ID: 13679471
[No Abstract] [Full Text] [Related]
9. The evolution of aldosterone antagonists.
Garthwaite SM; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):27-31. PubMed ID: 15134797
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone. Pharmacia.
Liew D; Martin J; Krum H
Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone as a target in congestive heart failure.
Rajagopalan S; Pitt B
Med Clin North Am; 2003 Mar; 87(2):441-57. PubMed ID: 12693733
[TBL] [Abstract][Full Text] [Related]
14. Eplerenone's role in the management of complex cardiovascular disorders.
Stewart Coats AJ; Shewan L
Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
16. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
17. The role of aldosterone receptor blockade in the management of cardiovascular disease.
Liew D; Krum H
Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
[TBL] [Abstract][Full Text] [Related]
18. [Eplerenone for treatment of heart failure].
Yoshimura M
Nihon Rinsho; 2007 May; 65 Suppl 5():153-8. PubMed ID: 17569313
[No Abstract] [Full Text] [Related]
19. Mineralocorticoid receptor antagonists.
Parthasarathy HK; MacDonald TM
Curr Hypertens Rep; 2007 Mar; 9(1):45-52. PubMed ID: 17362671
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
